Vertex Pharmaceuticals Inc (VRTX)

Mexico
Currency in MXN
9,360.00
0.00(0.00%)
Delayed Data·
VRTX Scorecard
Full Analysis
Management has been aggressively buying back shares
Fair Value
Day's Range
9,360.009,360.00
52 wk Range
6,735.0010,477.52
Key Statistics
Edit
Bid/Ask
9,500.00 / 10,290.16
Prev. Close
9,360
Open
9,360
Day's Range
9,360-9,360
52 wk Range
6,735-10,477.52
Volume
-
Average Volume (3m)
508
1-Year Change
40.2%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VRTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Vertex Pharmaceuticals Inc Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Employees
6100
Market
Mexico

Compare VRTX to Peers and Sector

Metrics to compare
VRTX
Peers
Sector
Relationship
P/E Ratio
−236.4x−0.2x−0.5x
PEG Ratio
2.040.000.00
Price/Book
7.7x0.5x2.6x
Price / LTM Sales
11.5x0.8x2.9x
Upside (Analyst Target)
-200.7%57.2%
Fair Value Upside
Unlock25.3%8.9%Unlock

Earnings

Latest Release
Feb 13, 2025
EPS / Forecast
3.50 / --
Revenue / Forecast
2.91B / --
EPS Revisions
Last 90 days

People Also Watch

278.89
AMGN
+0.35%
65.52
CVS
-0.08%
688.66
MCK
-0.52%
426.45
UNH
-0.35%

FAQ

What Is the Vertex (VRTX) Stock Price Today?

The Vertex stock price today is 9,360.00

What Stock Exchange Does Vertex Trade On?

Vertex is listed and trades on the Mexico stock exchange.

What Is the Stock Symbol for Vertex?

The stock symbol for Vertex is "VRTX."

What Is the Vertex Market Cap?

As of today, Vertex market cap is 2.47T.

What is Vertex Earnings Per Share?

The Vertex EPS is -2.08.

From a Technical Analysis Perspective, Is VRTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.